Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis
Authors:
- 1 August 2017
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 67 (2) , 263-271
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor PibrentasvirAntimicrobial Agents and Chemotherapy, 2017
- High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated CirrhosisGastroenterology, 2016
- Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 InfectionAntimicrobial Agents and Chemotherapy, 2016
- Direct‐acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN‐free treatment and future perspectivesLiver International, 2016
- Global epidemiology and genotype distribution of the hepatitis C virus infectionJournal of Hepatology, 2014
- Global distribution and prevalence of hepatitis C virus genotypesHepatology, 2014
- New Hepatitis C Therapies: The Toolbox, Strategies, and ChallengesGastroenterology, 2014
- The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigmJournal of Viral Hepatitis, 2014
- Review article: HCV genotype 3 – the new treatment challengeAlimentary Pharmacology & Therapeutics, 2014
- The impact of hepatitis C burden: an evidence‐based approachAlimentary Pharmacology & Therapeutics, 2014